+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2017-01-24Number of Pages: 124

Short Bowel Syndrome Market (Drug Class - GLP-2, Growth Hormone, and Glutamine) - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2016 - 2024

1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives
     1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Short Bowel Syndrome

4. Market Overview
     4.1. Introduction
            4.1.1. Drug Class Definition
            4.1.2. Industry Evolution / Developments
     4.2. Market Dynamics
            4.2.1. Drivers
            4.2.2. Restraints
            4.2.3. Opportunity     
     4.3. Global Short Bowel Syndrome Analysis and Forecasts, 2014–2024
            4.3.3. Market Revenue Projections (US$ Mn)
     4.4. Porter’s Five Force Analysis
     4.5. Value Chain Analysis
     4.6. Market Outlook
     4.7. Disease Overview
     4.8. Disease Epidemiology
     4.9. Patent Information
     4.10. Overview of Clinical Trials
     4.11. Qualitative Analysis of GLP-2 product
     4.12. Mode of action of SBS drugs
     4.13. Regulatory Scenario

5. Global Short Bowel Syndrome Analysis and Forecasts, By Drug Class 
     5.1. Introduction & Definition
     5.2. Key Findings / Developments
     5.3. Key Trends     
     5.4. Market Value (US$ Mn) Forecast By Drug Class, 2014–2024
            5.4.1. GLP-2 
            5.4.2. Growth Hormone
            5.4.3. Glutamine
            5.4.4. Others
     5.5. Market Attractiveness by Drug Class 

6. Global Short Bowel Syndrome Analysis and Forecasts, By Region
     6.1. Key Findings
     6.2. Market Value (US$ Mn) Forecast By Region
            6.2.1. North America  
            6.2.2. Europe 
            6.2.3. Rest of the World 
     6.3. Market Attractiveness by Country/Region

7. North America Short Bowel Syndrome Analysis and Forecast
     7.1. Introduction
            7.1.1. Key Findings
            7.1.2. Key Trends
     7.2. Market Value (US$ Mn) Forecast By Drug Class, 2014–2024
            7.2.1. GLP-2 
            7.2.2. Growth Hormone
            7.2.3. Glutamine
            7.2.4. Others
     7.3. Market Value (US$ Mn) Forecast By Country, 2014–2024
            7.3.1. U.S. 
            7.3.2. Canada
     7.3. Market Attractiveness Analysis 
            7.3.1. By Drug Class 
            7.3.2. By Country

8. Europe Short Bowel Syndrome Analysis and Forecast
     8.1. Introduction
            8.1.1. Key Findings
            8.1.2. Key Trends
     8.2. Market Value (US$ Mn) Forecast By Drug Class, 2014–2024
            8.2.1. GLP-2 
            8.2.2. Growth Hormone
            8.2.3. Glutamine
            8.2.4. Others
     8.3. Market Value (US$ Mn) Forecast By Country, 2014–2024
            8.3.1. U.K.
            8.3.2. Germany
            8.3.3. France
            8.3.4. Italy
            8.3.5. Spain
            8.3.6. Rest of Europe
     8.4. Market Attractiveness Analysis 
            8.4.1. By Drug Class 
            8.4.2. By Country

9. Rest of the World Short Bowel Syndrome Analysis and Forecast
     9.1. Introduction
     9.2. Market Value (US$ Mn) Forecast By Drug Class, 2014–2024
     9.3. Regional Insights
            9.3.1. Japan
            9.3.2. India
            9.3.3. Australia/New Zealand
            9.3.4. China
            9.3.5. Middle East
            9.3.6. Brazil

10. Competition Landscape
     10.1. Market Player – Competition Matrix (By Tier and Size of companies)
     10.2. Market Share Analysis by Company (2015)
     10.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
            10.3.1. Ardelyx, Inc.
                      10.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                      10.3.1.2. Business Overview
                      10.3.1.3. Product Portfolio 
                      10.3.1.4. Financial Overview 
                      10.3.1.5. SWOT Analysis 
                      10.3.1.6. Strategic overview
            10.3.2. Emmaus Life Sciences, Inc.
                      10.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                      10.3.2.2. Business Overview
                      10.3.2.3. Product Portfolio 
                      10.3.2.4. Financial Overview 
                      10.3.2.5. SWOT Analysis 
                      10.3.2.6. Strategic overview
            10.3.3. GLyPharma Therapeutic, Inc.
                      10.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                      10.3.3.2. Business Overview
                      10.3.3.3. Product Portfolio 
                      10.3.3.4. Financial Overview 
                      10.3.3.5. SWOT Analysis 
                      10.3.3.6. Strategic overview
            10.3.4. Merck KGaA
                      10.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                      10.3.4.2. Business Overview
                      10.3.4.3. Product Portfolio 
                      10.3.4.4. Financial Overview 
                      10.3.4.5. SWOT Analysis 
                      10.3.4.6. Strategic overview
            10.3.5. Naia Pharmaceuticals, Inc.
                      10.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                      10.3.5.2. Business Overview
                      10.3.5.3. Product Portfolio 
                      10.3.5.4. Financial Overview 
                      10.3.5.5. SWOT Analysis 
                      10.3.5.6. Strategic overview
            10.3.6. Nutrinia Ltd.
                      10.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                      10.3.6.2. Business Overview
                      10.3.6.3. Product Portfolio 
                      10.3.6.4. Financial Overview 
                      10.3.6.5. SWOT Analysis 
                      10.3.6.6. Strategic overview
            10.3.7. OxThera
                      10.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
                      10.3.7.2. Business Overview
                      10.3.7.3. Product Portfolio 
                      10.3.7.4. Financial Overview 
                      10.3.7.5. SWOT Analysis 
                      10.3.7.6. Strategic overview
            10.3.8. Sancilio & Company, Inc.
                      10.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
                      10.3.8.2. Business Overview
                      10.3.8.3. Product Portfolio 
                      10.3.8.4. Financial Overview 
                      10.3.8.5. SWOT Analysis 
                      10.3.8.6. Strategic overview
            10.3.9. Shire plc
                      10.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
                      10.3.9.2. Business Overview
                      10.3.9.3. Product Portfolio 
                      10.3.9.4. Financial Overview 
                      10.3.9.5. SWOT Analysis 
                      10.3.9.6. Strategic overview
            10.3.10. Zealand Pharma A/S
                      10.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
                      10.3.10.2. Business Overview
                      10.3.10.3. Product Portfolio 
                      10.3.10.4. Financial Overview 
                      10.3.10.5. SWOT Analysis 
                      10.3.10.6. Strategic overview

List of Figures

Figure 01: Global Short Bowel Syndrome Size (US$ Mn) and Forecast, 2016–2024
Figure 02: Global Market Value Share, by Drug Class (2016)
Figure 03: Global Market Value Share, by Region (2016)
Figure 04: Causes of SBS in neonates in neonatal intensive care units (NICU)
Figure 05: Causes of SBS in adults
Figure 06: Global Short Bowel Syndrome Market Value Share Analysis, by Drug Class, 2015 and
Figure 07: Global GLP-2 Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 08: Global Growth Hormone Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 09: Global Glutamine Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 10: Global Others Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 11: Short Bowel Syndrome Market Attractiveness Analysis, by Drug Class
Figure 12: Global Short Bowel Syndrome Market Revenue, US$ Mn, 2014–2024
Figure 13: Global Short Bowel Syndrome Market Value Share Analysis, by Region, 2015 and 2024
Figure 14: Short Bowel Syndrome Market Attractiveness Analysis, by Region
Figure 15: North America Short Bowel Syndrome Market Size (US$ Mn) Forecast, 2014–2024
Figure 16: North America Market Attractiveness Analysis, by Drug Class
Figure 17: North America Market Attractiveness Analysis, by Country
Figure 18: North America Short Bowel Syndrome Market Value Share Analysis, by Drug Class, 2015 and 2024
Figure 19: North America Short Bowel Syndrome Market Value Share Analysis, by Country, 2015 and 2024 
Figure 20: Europe Short Bowel Syndrome Market Size (US$ Mn) Forecast, 2014–2024
Figure 21: Europe Market Attractiveness Analysis, by Drug Class
Figure 22: Europe Market Attractiveness Analysis, by Country
Figure 23: Europe Short Bowel Syndrome Market Value Share Analysis, by Drug Class, 2015 and 2024
Figure 24: Europe Short Bowel Syndrome Market Value Share Analysis, by Country, 2015 and 2024
Figure 25: Rest of the World Short Bowel Syndrome Market Size (US$ Mn) Forecast, 2014–2024
Figure 26: Global Short Bowel Syndrome Market Share Analysis, by Company (2015)

List of Tables

Table 01: Overview of clinical trials for short bowel syndrome
Table 02: Global Short Bowel Syndrome Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
Table 03: Global Short Bowel Syndrome Market Size (US$ Mn) Forecast, by Region, 2014–2024
Table 04: North America Short Bowel Syndrome Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
Table 05: North America Short Bowel Syndrome Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 06: Europe Short Bowel Syndrome Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
Table 07: Europe Short Bowel Syndrome Market Size (US$ Mn) Forecast, by Country, 2014–2024    


 
 
Back To Top